Cytosorbents Co. (NASDAQ:CTSO) Short Interest Up 27.3% in April

Cytosorbents Co. (NASDAQ:CTSOGet Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 2,050,000 shares, a growth of 27.3% from the April 15th total of 1,610,000 shares. Currently, 5.3% of the company’s stock are sold short. Based on an average daily volume of 191,300 shares, the days-to-cover ratio is currently 10.7 days.

NASDAQ:CTSO traded up $0.09 during mid-day trading on Tuesday, hitting $2.22. 3,238 shares of the company traded hands, compared to its average volume of 294,798. The firm has a market cap of $96.70 million, a price-to-earnings ratio of -3.19 and a beta of 0.49. The stock’s fifty day moving average price is $2.75 and its 200-day moving average price is $3.83. Cytosorbents has a one year low of $1.78 and a one year high of $9.80.

Cytosorbents (NASDAQ:CTSOGet Rating) last posted its earnings results on Tuesday, May 3rd. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). Cytosorbents had a negative return on equity of 44.65% and a negative net margin of 71.16%. During the same period in the previous year, the company earned ($0.10) earnings per share. As a group, equities research analysts expect that Cytosorbents will post -0.61 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Neuberger Berman Group LLC boosted its position in Cytosorbents by 48.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,260,574 shares of the medical research company’s stock valued at $10,203,000 after acquiring an additional 413,485 shares in the last quarter. Avenir Corp boosted its position in Cytosorbents by 28.1% during the 4th quarter. Avenir Corp now owns 1,787,275 shares of the medical research company’s stock valued at $7,489,000 after acquiring an additional 391,890 shares in the last quarter. Skylands Capital LLC boosted its position in shares of Cytosorbents by 9.3% in the 1st quarter. Skylands Capital LLC now owns 2,127,952 shares of the medical research company’s stock worth $6,788,000 after purchasing an additional 181,578 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Cytosorbents by 129.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 298,877 shares of the medical research company’s stock worth $954,000 after purchasing an additional 168,712 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Cytosorbents by 262.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 222,856 shares of the medical research company’s stock worth $1,810,000 after purchasing an additional 161,369 shares in the last quarter. Hedge funds and other institutional investors own 40.98% of the company’s stock.

A number of research analysts have issued reports on CTSO shares. B. Riley lowered their price objective on Cytosorbents from $7.00 to $6.00 in a research note on Wednesday, May 4th. StockNews.com assumed coverage on Cytosorbents in a research note on Thursday, March 31st. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Cytosorbents currently has a consensus rating of “Buy” and an average price target of $9.67.

Cytosorbents Company Profile (Get Rating)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.

Read More

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.